Alpha-Synuclein Amplification Assay Aids Early Detection, With Potential to Improve Diagnosis and Treatment in Parkinson Disease

Parkinson's diagnosis

Neurology Live, April 12, 2023

In a newly published cross-sectional study in The Lancet Neurology, sponsored by The Michael J. Fox Foundation for Parkinson’s Research (MJFF)use of an alpha-synuclein seed amplification assay (αSyn-SAA) technique showed high diagnostic accuracy of Parkinson disease (PD), distinguished molecular subtypes, and detected the disease…READ MORE

Please Note: Important Billing Info

To improve patient access to the SYNTap® Biomarker CSF Test, Amprion offers the following billing options:

  • List price of $1500, with courtesy billing for both Medicare and private insurance.
  • An affordable self-pay price of $995 (patients may qualify for financial assistance and/or interest-free payment options).
  • Prices are effective as of January 1, 2024, and are subject to change.


Please note: Amprion is a Medicare participating provider, however, the SYNTap test does not currently have Medicare coverage determination. Also, Amprion is not yet in network with most insurers.

The SYNTap Biomarker CSF Test has been issued a dedicated CPT® PLA code to be used when billing: 0393U.

For additional information, please visit our billing page.